ArticleJournal for immunotherapy of cancer2025

Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells.

Franziska Füchsl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.